Gastrointestinal Risks Associated with Long‑Term Meloxicam (NSAID) Therapy

Risk Estimates

In the general adult population, the one‑year risk of serious gastrointestinal (GI) bleeding from chronic NSAID use ranges from approximately 1 in 2,100 for individuals younger than 45 years to 1 in 110 for individuals older than 75 years【1】.
Among patients with a prior history of ulcer disease, the risk of recurrent GI bleeding is about 5 % within 6 months, even when a COX‑2‑selective inhibitor or a proton‑pump inhibitor (PPI) is co‑prescribed【1】.

For patients identified as high‑risk for GI complications, concomitant gastro‑protective therapy (e.g., a PPI or misoprostol) should be considered【1】.
Use of anticoagulant medications together with meloxicam markedly increases the risk of GI bleeding, approximately 5–6‑fold compared with NSAID use alone【1】.

In the United States, NSAID‑related GI bleeding results in an estimated 32,000 hospitalizations and 3,200 deaths each year, underscoring the public‑health significance of careful duration and risk assessment【1】.